Nuclear Factor κB is required for tumor growth inhibition mediated by enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Purcell, James W ^a   Kim, Han K ^a   Tanlimco, Sonia G ^a   Doan, Minhtam ^a   Fox, Melvin ^a   Lambert, Peter ^a   Chao, Debra T ^a   Sho, Mien ^a   Wilson, Keith E ^a   Starling, Gary C ^a   Culp, Patricia A ^a  

^a ABBVIE INC   (United States)

Author keywords

Enavatuzumab; Fn14; Monoclonal antibody; NF B; P21; TweakR

Indexed keywords

ENAVATUZUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR RECEPTOR; TWEAKR; UNCLASSIFIED DRUG; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL DIVISION; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; WESTERN BLOTTING; DOWNSTREAM PROCESSING; FLOW CYTOMETRY; FLUORESCENCE IMAGING; GENE MUTATION; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH INHIBITION RATE;

EID: 84987842175     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Hu S, Tamada K, Ni J, Vincenz C, Chen L. Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily. Genomics (1999) 62:103-7. doi: 10.1006/geno.1999.5979.
2. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J (2003) 371:395-403. doi:10.1042/BJ20021730.
3. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov (2008) 7:411-25. doi:10.1038/nrd2488.
4. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem (1997) 272:32401-10. doi:10.1074/jbc.272.51.32401.
5. Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, Benjamin CD, et al. Dual role for TWEAK in angiogenic regulation. J Cell Sci (2002) 115:267-74.
6. Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci (2004) 9:2273-84. doi:10.2741/1395.
7. Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J (2006) 25:5826-39. doi:10.1038/sj.emboj.7601441.
8. Tran NL, Mcdonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res (2006) 66:9535-42. doi:10.1158/0008-5472.CAN-06-0418.
9. Han S, Yoon K, Lee K, Kim K, Jang H, Lee NK, et al. TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochem Biophys Res Commun (2003) 305:789-96. doi:10.1016/S0006-291X(03)00852-0.
10. De Ketelaere A, Vermeulen L, Vialard J, Van De Weyer I, Van Wauwe J, Haegeman G, et al. Involvement of GSK-3beta in TWEAK-mediated NF-kappaB activation. FEBS Lett (2004) 566:60-4. doi:10.1016/j.febslet.2004.04.041.
11. Roos C, Wicovsky A, Muller N, Salzmann S, Rosenthal T, Kalthoff H, et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol (2010) 185:1593-605. doi:10.4049/jimmunol.0903555.
12. Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, et al. Multiple pathways of TWEAK-induced cell death. J Immunol (2002) 168:734-43.
13. Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, et al. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol (2003) 170:341-8.
14. Michaelson JS, Burkly LC. Therapeutic targeting of TWEAK/Fn14 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ (2009) 49:145-60. doi:10.1007/400_2008_18.
15. Chao DT, Su M, Tanlimco S, Sho M, Choi D, Fox M, et al. Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol (2013) 139:315-25. doi:10.1007/s00432-012-1332-x.
16. Winkles JA, Tran NL, Berens ME. TWEAK and Fn14: new molecular targets for cancer therapy? Cancer Lett (2006) 235:11-7. doi:10.1016/j.canlet.2005.03.048.
17. Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res (2010) 16:497-508. doi:10.1158/1078-0432.CCR-09-1929.
18. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 14:649-83. doi:10.1146/annurev.immunol.14.1.649.
19. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ (2006) 13:738-47. doi:10.1038/sj.cdd.4401877.
20. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res (2003) 63:4196-203.
21. Waelchli R, Bollbuck B, Bruns C, Buhl T, Eder J, Feifel R, et al. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK. Bioorg Med Chem Lett (2006) 16:108-12. doi:10.1016/j.bmcl.2005.09.035.
22. Tran NL, Mcdonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem (2005) 280:3483-92. doi:10.1074/jbc.M409906200.
23. Whiteside ST, Israel A. I kappa B proteins: structure, function and regulation. Semin Cancer Biol (1997) 8:75-82. doi:10.1006/scbi.1997.0058.
24. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 2006:re13. doi:10.1126/stke.3572006re13.
25. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science (1997) 275:523-7. doi:10.1126/science.275.5299.523.
26. Basile JR, Eichten A, Zacny V, Munger K. NF-kappaB-mediated induction of p21(Cip1/Waf1) by tumor necrosis factor alpha induces growth arrest and cytoprotection in normal human keratinocytes. Mol Cancer Res (2003) 1:262-70.
27. Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs (2011) 3:362-75. doi:10.4161/mabs.3.4.16090.
28. Brown SA, Ghosh A, Winkles JA. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem (2010) 285:17432-41. doi:10.1074/jbc.M110.131979.
29. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem (2003) 278:36005-12. doi:10.1074/jbc.M304266200.
30. Sanz AB, Sanchez-Nino MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, et al. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One (2010) 5:e8955. doi:10.1371/journal.pone.0008955.
31. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J (1995) 14:2876-83.
32. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science (2002) 298:1241-5. doi:10.1126/science.1071914.
33. Werner SL, Barken D, Hoffmann A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science (2005) 309:1857-61. doi:10.1126/science.1113319.
34. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, Paramo JA, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis (2009) 207:103-10. doi:10.1016/j.atherosclerosis.2009.04.033.
35. Higuchi M, Aggarwal BB. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol (1994) 152:3550-8.
36. Fischer R, Maier O, Naumer M, Krippner-Heidenreich A, Scheurich P, Pfizenmaier K. Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFkappaB pathway. Cell Signal (2011) 23:161-70. doi:10.1016/j.cellsig.2010.08.016.
37. Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, et al. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem (2013) 288:13455-66. doi:10.1074/jbc.M112.435917.
38. Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, Scheurich P, et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol (1999) 29:1785-92. doi:10.1002/t1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U.
39. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol (2008) 182:171-84. doi:10.1083/jcb.200801010.
40. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest (2001) 107:241-6. doi:10.1172/JCI11991.
41. Piva R, Belardo G, Santoro MG. NF-kappaB: a stress-regulated switch for cell survival. Antioxid Redox Signal (2006) 8:478-86. doi:10.1089/ars.2006.8.478.
42. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem (2010) 336:25-37. doi:10.1007/s11010-009-0267-2.
43. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ (2006) 13:759-72. doi:10.1038/sj.cdd.4401838.